CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [3] - The company is commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023 [3] - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [3] Upcoming Events - CorMedix will participate in the Jefferies Global Healthcare Conference in New York from June 3 to June 5, 2025 [1] - The presentation at the conference is scheduled for June 5, 2025, at 3:45 p.m. EDT [2] Future Developments - The company is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 [3] - CorMedix intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas [3]